Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 7 October 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 9 August 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.6 billion in the period from 9 August 2019 to 30 October 2019.
Since the announcement as of 30 September 2019, the following transactions have been made:
Number of B shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 4,586,950 | 1,600,720,816 | |
30 September 2019 | 125,000 | 354.18 | 44,272,301 |
1 October 2019 | 125,000 | 350.59 | 43,824,224 |
2 October 2019 | 125,000 | 342.86 | 42,857,789 |
3 October 2019 | 130,000 | 339.19 | 44,094,187 |
4 October 2019 | 130,000 | 347.06 | 45,117,655 |
Accumulated under the programme | 5,221,950 | 1,820,886,972 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 35,781,994 B shares of DKK 0.20, corresponding to 1.5% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 4 October, Novo Nordisk has since 1 February 2019 repurchased a total of 28,622,962 B shares at an average share price of DKK 330.36 per B share equal to a transaction value of DKK 9,455,840,426.
Further information
Media: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 240 9429 | kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
Kristoffer Due Berg (US) | +1 609 235 2989 | krdb@novonordisk.com |
Company announcement no. 57 / 2019
Attachment
Upcoming Life Sciences Events
- April 2024
- Pharma-Biotech Product & Company Valuation - An Introductory
- Basel: Swiss Biotech Day 2024
- London: BioTrinity 2024